Presentation - Quality requirements for nanomedicines which role for the European Pharmacopoeia - Introduction session

Cancer nanomedicines: Principles, progress, products, problems and prospects by Twan Lammers, RWTH Aachen University, Germany A short introduction to the European Pharmacopoeia (Ph. Eur.) by Emmanuelle Charton & Dirk Leutner, EDQM, Council of Europe Nano-related activities at the Ph. Eur. (NBC and vaccines) by Gerrit Borchard, Chair of the Non-Biological Complex Drugs (NBC) Working Party, University of Geneva, Switzerland and Gwenaël Cirefice, Secretary to Group of Experts on Human Vaccines (15), EDQM, Council of Europe

View in context